Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KALA
KALA logo

KALA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy KALA BIO Inc (KALA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
2.090
1 Day change
-17.06%
52 Week Range
1030.000
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Given the lack of strong buy signals, insider selling trends, and absence of positive news or financial performance data, KALA BIO Inc is not a strong buy for a beginner long-term investor at this time. The stock should be held until clearer positive catalysts or financial data emerge.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 78.755, and moving averages are converging, suggesting no clear trend. The stock closed near its resistance level (R1: 3.4), with a significant regular market change of 26.89%, but post-market change is negative at -3.34%.

Positive Catalysts

  • The MACD indicates bullish momentum, and the stock has shown a strong regular market gain of 26.89%.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 177.30% increase in selling activity over the last month. There is no recent news or congress trading data to support a positive outlook. Additionally, the stock has a 60% chance of a minor decline (-1.05%) over the next month.

Financial Performance

No financial data available due to an error in the snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data provided.

Wall Street analysts forecast KALA stock price to rise
Analyst Rating
0
Wall Street analysts forecast KALA stock price to rise
Buy
Hold
Sell
0
Current: 2.090
sliders
Low
0
Averages
0
High
0
0
Current: 2.090
sliders
Low
0
Averages
0
High
0
Morgan Stanley
Overweight
maintain
$28 -> $30
AI Analysis
2026-01-08
Reason
Morgan Stanley
Price Target
$28 -> $30
AI Analysis
2026-01-08
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Cullinan Therapeutics to $30 from $28 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$26 -> $27
2026-01-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$26 -> $27
2026-01-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Cullinan Therapeutics to $27 from $26 and keeps a Buy rating on the shares after the company announced its 2026 milestones.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KALA
Unlock Now

People Also Watch